Alice Indini is a medical oncologist working at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. She received her medical degree from the University of Milan in 2012, and is board certified as an oncologist physician. Dr. Indini’s main research interests are cutaneous tumors (melanoma, non-melanoma skin cancer), Kaposi’s sarcoma, and immunotherapy. She contributed in creating a multidisciplinary team for the management of patients with skin cancers at the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, with the long-standing experience of the Dermatology school of the University of Milan. Dr. Indini is an active member of the Italian Melanoma Intergroup (IMI), and takes active part in the development and management of clinical and research activities in the field of melanoma. In 2020, dr. Indini received the approval of the MSD MISP drug-only concept “A Phase II single-arm study of pembrolizumab plus lenvatinib in previously treated Classic Kaposi’s Sarcoma (CKS)”, which she is currently leading as Principal Investigator. She has actively taken part on clinical phase I-III trials of pediatric and adult oncology, as sub-investigator. Dr. Indini has a lively clinical research activity, with production of papers on cutaneous neoplasms, immunotherapy and gynecologic tumors. She is part of the reviewer board of peer-reviewed journal, including the Lancet Oncology and the European Journal of Cancer.